Uganda: First vaccination for GMZ2 malaria vaccine trial

09 May 2011
The Medical News
Today, the EDCTP-funded GMZ2 consortium starts volunteer enrolment for the phase IIb clinical trial of the candidate malaria vaccine GMZ2 in Uganda. This is the third trial site to initiate volunteer recruitment for this multi-country study. Vaccination is already underway at trial sites in Gabon (November 2010) and Burkina Faso (April 2011). The Uganda site is in the peri-urban area of Iganga/Mayuge, at the Iganga Hospital. Akin to most areas in Uganda, malaria is one of the major health problems in this district. A team from Makerere University (Kampala) is conducting the trial.

The GMZ2 vaccine is a hybrid malaria vaccine composed of merozoite surface protein (MSP3) and glutamate rich protein (GLURP). The vaccine is adjuvanted with aluminium hydroxide. The targeted total for vaccination is 1870 children between 1 and 5 years of age. The Faculty of Medicine is the largest faculty of Makerere University, Uganda's leading university. It is an experienced academic and research institution that has conducted research in infectious diseases, degenerative diseases, reproductive health, mental health, and others. All research work is reviewed and approved by an Institutional Ethical Review Board with oversight from the Uganda National Council of Science and Technology. Between 2006 and 2009 the Faculty strengthened its capacity to supervise and monitor research on human subjects through an EDCTP-funded project.